Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say

Amphastar Pharmaceuticals (AMPH) reported Q2 2025 revenue of $174.41 million, a 4.4% year-over-year decrease, yet it surpassed the Zacks consensus estimate by 2.69%. EPS came in at $0.85, down from $0.94 year-over-year, but delivered a significant 19.72% positive surprise against expectations. The overall revenue decline was notably impacted by substantial drops in Glucagon (-24.7%) and Epinephrine (-42.1%) sales, despite growth in Lidocaine. Shares of AMPH have underperformed the S&P 500 over the past month, returning -7.2% compared to the index's +1.2%, though the stock currently holds a Zacks Rank #2 (Buy).

Analysis

Amphastar Pharmaceuticals reported a mixed second quarter, characterized by significant beats on consensus estimates but concerning year-over-year declines. While total revenue of $174.41 million and EPS of $0.85 surpassed Wall Street expectations by 2.69% and 19.72% respectively, these figures represent year-over-year contractions of 4.4% for revenue and 9.6% for EPS. The underlying product-level performance reveals significant weakness in key segments, which drove the overall top-line decline. Specifically, revenue from Glucagon fell 24.7% and Epinephrine plunged 42.1% from the prior year, both also missing analyst estimates. This was only partially offset by a strong 17.2% growth in Lidocaine sales, which beat expectations. Despite the positive earnings surprise, the market appears focused on the negative growth trend and segment weakness, as reflected in the stock's -7.2% return over the past month, starkly underperforming the S&P 500. The current Zacks Rank #2 (Buy) presents a conflicting signal, suggesting a potential for near-term outperformance that contrasts with the stock's recent price action and fundamental YoY deterioration.

Key Decisions for Investors

• Investors should weigh the significant EPS beat of 19.72% against the fundamental deterioration shown by the 4.4% year-over-year revenue decline, suggesting low analyst expectations may have masked underlying business challenges.
• Closely monitor the performance of the Glucagon and Epinephrine segments, as their sharp revenue contractions of 24.7% and 42.1% respectively are the primary drivers of weakness and their stabilization is critical for a potential turnaround.
• Consider the divergence between the stock's recent -7.2% underperformance and its Zacks Rank #2 (Buy) rating, which may indicate that negative sentiment is already priced in, presenting a potential tactical opportunity for those aligned with the bullish analyst outlook.